MALIKA AMMOR: Open Payments
NPI 1942828835 · FRAMINGHAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,959 in 81 payments from 31 companies in 2025. Trend: 2023 $882 · 2024 $1,083 · 2025 $5,959
Food & beverage: $3,282Travel & lodging: $2,562Education: $115
| Company | Payments | Amount |
|---|---|---|
| MERZ NORTH AMERICA, INC. | 32 | $4,587 |
| Janssen Biotech, Inc. | 3 | $150 |
| REVANCE THERAPEUTICS, INC. | 3 | $145 |
| PFIZER INC. | 5 | $133 |
| AstraZeneca Pharmaceuticals LP | 3 | $92 |
| Merck Sharp & Dohme LLC | 3 | $85 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $76 |
| Daiichi Sankyo Inc. | 2 | $59 |
| Eisai Inc. | 2 | $55 |
| GENZYME CORPORATION | 2 | $53 |
Products named: Xeomin, DAXXIFY, RYBREVANT, KEYTRUDA, Nubeqa, LYNPARZA, ELREXFIO, Lenvima.
Industry payments across MA — which companies pay providers there.
